Treatment with monoclonal antibodies in cancer - efficacy and prospects
DOI:
https://doi.org/10.12775/QS.2025.38.57845Keywords
Monoclonal bodies, combination therapy, anti-cancer therapy, HER2, BRCAAbstract
Objective:
This review paper examines the effectiveness and prospects of monoclonal antibody therapies in oncology. The development of these therapies has revolutionized targeted cancer treatment due to the specificity and molecular precision of the antibodies. The article discusses their mechanisms of action, clinical applications and new trends, with a special focus on the role of personalized therapies.
Materials and Methods:
The review covers key studies on monoclonal antibody therapies, analyzing their mechanisms of action, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The paper also considers the integration of these therapies with other treatments, such as chemotherapy and immunotherapy.
Main results:
Monoclonal antibodies have shown high efficacy in the treatment of various cancers, including breast, ovarian and lung cancers, by targeting specific antigens such as HER2 and PD-1/PD-L1. Advances in bispecific antibodies, drug-antibody conjugates and personalized biomarkers are further improving treatment outcomes. Challenges such as resistance and side effects are being addressed through genetic engineering and innovative drug delivery systems.
Conclusions:
Monoclonal antibody therapies have revolutionized cancer treatment, offering precise and personalized therapeutic approaches. Further research into combination therapies and new antibody technologies promises to overcome current limitations and expand their therapeutic potential.
References
[1] - Powroźnik B, Kubowicz P, Pękala E. Monoclonal antibodies in targeted therapy. Postepy Hig Med Dosw (Online). 2012 Sep 12;66:663-73. doi: 10.5604/17322693.1009980. PMID: 23001208.
[2] - Hooks MA, Wade CS, Millikan WJ Jr. Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation. Pharmacotherapy. 1991;11(1):26-37. PMID: 1902291.
[3] - Kufer P., Lutterbüse R., Baeuerle P.A.: A revival of bispecific antibodies. Trends Biotechnol., 2004; 22: 238-244
[4] - Kaur, R., Bhardwaj, A. & Gupta, S. Cancer treatment therapies: traditional to modern approaches to combat cancers. Mol Biol Rep 50, 9663-9676 (2023). https://doi.org/10.1007/s11033-023-08809-3
[5] - Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J, Castro HR, Mansoor W, Braghiroli MI, Karaseva N, Caglevic C, Villanueva L, Goekkurt E, Satake H, Enzinger P, Alsina M, Benson A, Chao J, Ko AH, Wainberg ZA, Kher U, Shah S, Kang SP, Tabernero J. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020 Oct 1;6(10):1571-1580. doi: 10.1001/jamaoncol.2020.3370. PMID: 32880601; PMCID: PMC7489405.
[6] - Zsiros E, Lynam S, Attwood KM, Wang C, Chilakapati S, Gomez EC, Liu S, Akers S, Lele S, Frederick PJ, Odunsi K. Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2021 Jan 1;7(1):78-85. doi: 10.1001/jamaoncol.2020.5945. PMID: 33211063; PMCID: PMC7677872.
[7] - Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kemmer K, Helsten T, Majure M, Stringer-Reasor E, Parker C, Lee MC, Haddad T, Cohen RN, Asare S, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Schwab R, Symmans WF, van 't Veer L, Yee D, DeMichele A, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Berry DA, Esserman LJ. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA Oncol. 2020 May 1;6(5):676-684. doi: 10.1001/jamaoncol.2019.6650. PMID: 32053137; PMCID: PMC7058271.
[8] - Ustyanovska Avtenyuk N, Visser N, Bremer E, Wiersma VR. The Neutrophil: The Underdog That Packs a Punch in the Fight against Cancer. Int J Mol Sci. 2020 Oct 22;21(21):7820. doi: 10.3390/ijms21217820. PMID: 33105656; PMCID: PMC7659937.
[9] - Issafras H, Fan S, Tseng CL, Cheng Y, Lin P, Xiao L, Huang YJ, Tu CH, Hsiao YC, Li M, Chen YH, Ho CH, Li O, Wang Y, Chen S, Ji Z, Zhang E, Mao YT, Liu E, Yang S, Jiang W. Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy. PLoS One. 2021 Dec 31;16(12):e0257972. doi: 10.1371/journal.pone.0257972. PMID: 34972111; PMCID: PMC8719770.
[10] - Zahavi DJ, Erbe R, Zhang YW, Guo T, Malchiodi ZX, Maynard R, Lekan A, Gallagher R, Wulfkuhle J, Petricoin E, Jablonski SA, Fertig EJ, Weiner LM. Antibody dependent cell-mediated cytotoxicity selection pressure induces diverse mechanisms of resistance. Cancer Biol Ther. 2023 Dec 31;24(1):2269637. doi: 10.1080/15384047.2023.2269637. epub 2023 Oct 25. PMID: 37878417; PMCID: PMC10601508.
[11] - Zahavi D, Weiner L. Monoclonal Antibodies in Cancer Therapy. Antibodies (Basel). 2020 Jul 20;9(3):34. doi: 10.3390/antib9030034. PMID: 32698317; PMCID: PMC7551545.
[12] - Monoclonal Antibodies Handbook of Internal Medicine - Practical Medicine. Available at: https://www.mp.pl/interna/chapter/B01.X.E.4.3.1 (Accessed: December 17, 2024).
[13] - Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: Treating cancer with specificity. Eur J Pharmacol. 2018 Sep 5;834:188-196. doi: 10.1016/j.ejphar.2018.07.034. epub 2018 Jul 20. PMID: 30031797.
[14] - Parray HA, Shukla S, Samal S, Shrivastava T, Ahmed S, Sharma C, Kumar R. Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives. Int Immunopharmacol. 2020 Aug;85:106639. doi: 10.1016/j.intimp.2020.106639. epub 2020 May 27. PMID: 32473573; PMCID: PMC7255167.
[15] - Nelson PN, Reynolds GM, Waldron EE, Ward E, Giannopoulos K, Murray PG. Monoclonal antibodies. Mol Pathol. 2000 Jun;53(3):111-7. doi: 10.1136/mp.53.3.111. PMID: 10897328; PMCID: PMC1186915.
[16] - Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, Chinot OL. Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020 Jun;86:102017. doi: 10.1016/j.ctrv.2020.102017. epub 2020 Mar 26. PMID: 32335505.
[17] - von Arx C, De Placido P, Caltavituro A, Di Rienzo R, Buonaiuto R, De Laurentiis M, Arpino G, Puglisi F, Giuliano M, Del Mastro L. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer. Cancer Treat Rev. 2023 Feb;113:102500. doi: 10.1016/j.ctrv.2022.102500. epub 2022 Dec 24. PMID: 36587473.
[18] - Sharma P, Stecklein SR, Yoder R, Staley JM, Schwensen K, O'Dea A, Nye L, Satelli D, Crane G, Madan R, O'Neil MF, Wagner J, Larson KE, Balanoff C, Kilgore L, Phadnis MA, Godwin AK, Salgado R, Khan QJ, O'Shaughnessy J. Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial. JAMA Oncol. 2024 Feb 1;10(2):227-235. doi: 10.1001/jamaoncol.2023.5033. PMID: 37991778; PMCID: PMC10666040.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Bartosz Omasta, Katarzyna Kamińska-Omasta, Olga Krupa, Daria Rybak, Kuba Borys Romańczuk, Magdalena Agata Czerska, Paulina Dorota Pietrukaniec, Szymon Przemysław Stolarczyk, Zofia Martyna Wójcik, Kinga Furtak
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 24
Number of citations: 0
